Insights – Medical

  1. Enabling the next BRS revolution

    By James M. Lindsey III, Senior Research Engineer

    First conceived in the early 1990s, bioresorbable vascular scaffolds (BRS) were developed to provide temporary arterial mechanical support and anti-proliferative effects similar to permanent metallic drug-eluting stents (DES), but then completely resorb into the body after a finite period of time, returning the vessel to its normal state. While metallic stents were (and still are)…

    Read More
  2. From head to toe: the expanding reach of endovascular therapy

    By Rodrigo Silva, Global Product Manager, Zeus.

    As endovascular treatment expands to the far reaches of the body, catheter innovation must keep pace. Never before has the need for catheters with a multitude of properties and functions been so great.

    Read More
  3. Next generation catheters: The trends shaping the future of catheter design

    By Matt Allen, Senior Product Manager

    Following COMPAMED 2019 in Dusseldorf, Matt Allen, Zeus’ Senior Product Manager, discusses the challenges facing catheter design today. Here’s his take on the exciting advances overcoming current obstacles, plus innovations coming down the line and what that means for future treatments.

    Read More
  4. Tie Layer: A breakthrough solution to catheter failure

    By Matt Allen, Senior Product Manager

    Product engineers at catheter manufacturing companies will be only too aware of the problem of delamination – the separation of material layers within the catheter. Typically, delamination issues are not detected until final testing, after catheter assembly is complete, incurring significantly high scrap costs for manufacturers.

    Read More
  5. Why emerging markets deserve more from medical device OEMs 

    By Daryl Leach, Director of Global Market Management, Zeus

    With emerging markets set to account for a third of the industry’s global revenue by 2022*, the growth opportunity for medical OEMs is enormous. Increased GDP and greater income per capita in developing countries means patients are becoming more proactive about their health. As a result, they can afford higher quality treatment plans and devices.

    Read More